Lexaria Bioscience Corp. has commenced dosing in Human Pilot Study #7 (GLP-1-H26-7) on June 14, 2026, evaluating two oral DehydraTECH-semaglutide compositions against Novo Nordisk's Wegovy tablets. The 5-week study aims to match or exceed the pharmacokinetic performance of Wegovy while preserving the safety profiles observed in previous GLP-1 studies. The results are expected to influence potential commercial partnerships focused on Lexaria's proprietary DehydraTECH technology.

The study investigates three separate arms to assess safety, tolerability, and pharmacokinetic properties. It compares SNAC-inclusive, DehydraTECH-semaglutide compositions in tablet and capsule formats to commercially available Wegovy tablets. The study is conducted under fasted pre-dose conditions, similar to Novo's oral semaglutide administration criteria, to allow for the achievement of steady-state concentration levels.

Study Enhancements

The study introduces two primary enhancements to Lexaria's DehydraTECH technology. First, an oral tablet DehydraTECH-semaglutide composition is being used for the first time, mimicking the physical properties of Rybelsus and Wegovy tablets to optimize absorption. Second, both tablet and capsule formulations include SNAC, evaluated over a multi-dose, multi-week period for the first time.

Study Arms and Comparison

The following table outlines the key components of the study arms:

Previous studies, including Human Pilot Studies #1 and #2 (GLP-1-H24-1 and GLP-1-H24-2), demonstrated pharmacokinetic performance matching or exceeding Rybelsus control arms with notable safety profiles. However, those studies were limited to single-dose designs. The current 5-week duration is designed to reach steady-state concentrations, providing a more comprehensive evaluation of the formulations.

The study is fully funded from existing corporate resources. Lexaria holds a robust intellectual property portfolio with 66 patents granted and additional patents pending worldwide for its DehydraTECH platform.

Lexaria Bioscience Corp. (NASDAQ: LEXX) announced that dosing has begun in its Animal Study #1 (GLP-1-A26-1) on June 10, 2026. The study evaluates formulation enhancements using DehydraTECH-semaglutide and DehydraTECH-CBD compositions to explore improved performance and establish new intellectual property claims. Results are expected by early September, barring interruptions.

The study utilizes Sprague-Dawley rats across 11 separate arms to quantify pharmacokinetic performance over an 8-24 hour post-dosing period. A key objective is to evaluate innovative alternative formulations to SNAC (salcaprozate sodium), currently used by Novo Nordisk in oral Rybelsus and Wegovy products. Lexaria has filed three new patent applications anticipating technological improvements in this area. The study will also measure drug concentrations in the brain, leveraging DehydraTECH's evidenced superior absorption into brain tissue.

Separately, Lexaria received its first Australian patent grant (#2023302884) in Family #21 for Pharmaceutical Compositions and Methods for Treating Hypertension on June 11, 2026. This is the company's 7th patent in this family, with a term until April 25, 2043. The company holds a robust intellectual property portfolio with 66 patents granted worldwide.

Study Design and Funding

The study includes one reference arm using an existing DHT-sema composition and another using an existing DHT-CBD composition. Lexaria will use proprietary historical data from these reference arms as baseline comparators. The study is fully funded from existing corporate resources.

Patent Portfolio Expansion

The recent Australian grant adds to Lexaria's global patent holdings. The company continues to pursue business development opportunities with commercial partners for its DehydraTECH technology, which aims to improve bio-absorption and reduce side effects.